REG - Cambridge Cognition - Exercise of Options and Total Voting Rights

Cambridge Cognition HoldingsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250929:nRSc1073Ba&default-theme=true

RNS Number : 1073B  Cambridge Cognition Holdings PLC  29 September 2025

 

29 September 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group
specialising in digital health products that advance brain health research and
treatment, announces that it has issued and allotted 589,287 new ordinary
shares of 1 pence each in the capital of the Company (the "New Ordinary
Shares") following an exercise of share options.

Application has been made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on AIM, with dealings expected to commence on
30 September 2025 ("Admission").

Following Admission, the Company will have a total of 46,629,700 Ordinary
Shares in issue. Shareholders may use this figure of 46,629,700 Ordinary
Shares as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                  Tel: 012 2381 0700 

 Rob Baker, Joint Managing Director                press@camcog.com (mailto:press@camcog.com)  

 and Chief Operating Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers        (Corporate Finance)

 Rupert Dearden                                    (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)            Tel: 020 3903 7715 

 David Poutney / Amber Higgs                        

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPKFBNOBKDDCB